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Background: Antidementia drugs have been associated with an increased risk of cardiovascular events.
The objective of this study was to identify the predictors for cardiovascular events among patients with
Alzheimer's disease (AD) on antidementia drugs, mining large longitudinal claims data.
Methods: Using 2006e2011 claims from a 5% random sample of Medicare beneﬁciaries, I identiﬁed
patients with AD who ﬁlled a prescription for an antidementia drug between 2007 and 2011. I followed
them from the initiation of the antidementia drug until a cardiovascular event or December 31, 2011,
censored by death or discontinuation of antidementia drugs. The outcome was the incidence of car-
diovascular events, which include acute myocardial infarction, bradycardia, syncope, atrioventricular
block, QT prolongation, and ventricular tachycardia. Covariates included predeﬁned patient character-
istics and empirical attributes identiﬁed from the claims, including International Classiﬁcation of Diseases,
Ninth Revision (ICD-9) diagnosis codes, Healthcare Common Procedure Coding System codes, and ther-
apeutic classes of all prescriptions ﬁlled. After using feature selection to choose the top covariates, a
logistic regression with multivariate variable selection was constructed.
Results: With an accuracy of 83.9% and a sensitivity of 93.3%, the algorithm identiﬁed 22 predictors for
cardiovascular events, including a history of ischemic heart disease, congestive heart failure, syncope,
stroke or transient ischemic attack, diabetes, number of other comorbidities, and procedures including
venipuncture and radiologic examinations.
Conclusion: The results of this study can help clinicians identify AD patients with a higher risk of car-
diovascular events who therefore should be prescribed antidementia drugs cautiously.
Copyright © 2016, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Alzheimer's disease (AD) is a neurodegenerative disease char-
acterized by progressive cognitive impairment affecting primarily
those 65 years of age and older. The prevalence of AD among
Medicare beneﬁciaries has been estimated at 5.1% in 2011.1 As the
number of older adults grows, the prevalence of AD will increase.
Although there is no cure for AD, four medications are available to
delay the cognitive impairment associated with AD, i.e., riva-
stigmine, galantamine, and donepezildall acetylcholinesterase
inhibitors (AChEIs), and the N-methyl-D-aspartic receptor antago-
nist memantine.cy and Management, Univer-
8, Pittsburgh, PA 15261, USA.
inical Gerontology & Geriatrics. Pub
d/4.0/).Four antidementia drugs have been associated with an
increased risk of cardiovascular events. In particular, there is evi-
dence of increased risk of syncope, bradycardia, QT interval pro-
longation, ventricular tachycardia, and atrioventricular block with
AChEIs.2e8 Moreover, memantine has been associated with an
increased risk of myocardial infarction,9 among other cardiovas-
cular events.10 Despite the severity of these events, most observa-
tional studies on the cardiovascular safety of antidementia drugs
are case or case series reports8,11e13 and therefore, it remains un-
known which factors place a higher risk for experiencing cardio-
vascular events while taking antidementia drugs.
Identifying clinical predictors for such events is of high rele-
vance for three reasons. First, most prescribers are not aware of
these events when prescribing antidementia drugs.3 Second, these
events occur in aged patients with a high burden of comorbidities
and who are at high risk for complications. Third, because there is
only limited evidence on the effectiveness of theselished by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
Table 1
Baseline characteristics of the study participants, by incidence of cardiovascular
event.
Variable (%) Free of
cardiovascular
event (N ¼ 128,398)
Experiencing
cardiovascular
event (N ¼ 31,698)
p
Age (y) <0.001
<65 4.15 3.69
65e79 34.12 33.14
>80 61.73 63.17
Male 27.76 30.06 <0.001
Race <0.001
White 76.03 75.59
Black 9.63 12.27
Asian 2.67 2.54
Hispanic 10.61 8.48
Native American 0.27 0.26
Other 0.69 0.86
Medicaid eligibility 41.96 50.20 <0.001
History of myocardial
infarction
4.07 7.26 <0.001
History of bradycardia 5.85 13.47 <0.001
History of syncope 10.32 22.66 <0.001
History of QT prolongation 0.04 0.09 <0.001
History of ventricular
tachycardia
0.93 2.67 <0.001
History of atrioventricular
block
0.6 2.74 <0.001
History of stroke or TIA 21.71 33.01 <0.001
Ischemic heart disease 46.38 67.21 <0.001
Congestive Heart Failure 31.50 46.43 <0.001
CMS priority cancera 10.14 12.82 <0.001
Other CMS comorbiditiesb <0.001
0e1 37.53 20.25
2e3 38.23 45.72
4 24.25 34.03
CMS¼ Centers for Medicare and Medicaid Services; TIA ¼ transient ischemic attack.
a CMS priority types of cancer include breast cancer, colorectal cancer, endome-
trial cancer, and lung cancer.
b The number of other CMS priority comorbidities was calculated as the sum of
history of cataract, chronic obstructive pulmonary disease, depression, glaucoma,
knee or hip replacement, osteoporosis, and rheumatoid arthritis or osteoarthritis.
I. Hernandez / Journal of Clinical Gerontology & Geriatrics 7 (2016) 77e8278medications,14e16 the beneﬁt/risk ratio of using antidementia drugs
for each patient is especially sensitive to the risk of adverse events.
As a result, it is important to use real-world data to identify the
risk factors for cardiovascular events in patients with AD taking
antidementia drugs. In this paper, I leveraged large longitudinal
claims data to identify predictors for cardiovascular events among
patients with AD and on antidementia drugs.
2. Methods
2.1. Data source and study population
Pharmacy and medical claims in 2006e2011 for a 5% random
sample of Medicare beneﬁciaries were obtained from the Centers
forMedicare andMedicaid Services (CMS). First, patients diagnosed
with AD were identiﬁed by using the CMS Chronic Condition
Warehouse indicator that traces the ﬁrst diagnosis date back to
January 1, 1999. The diagnosis of AD was deﬁned as having one
claim with primary or secondary International Classiﬁcation of Dis-
eases, Ninth Revision (ICD-9) code 331.0.17 Second, individuals who
ﬁlled at least one prescription for donepezil, rivastigmine, galant-
amine, or memantine between January 1, 2007 and December 31,
2011 were selected. Index date was deﬁned as the date of the ﬁrst
prescription ﬁlled for an antidementia drug after January 1, 2007.
The study sample included 109,331 donepezil patients, 15,021
rivastigmine patients, 2535 galantamine patients, and 33,209
memantine patients. Each individual was followed from index date
until cardiovascular event or December 31, 2011, censored by
discontinuation of antidementia drugs for > 45 days or death. The
study was declared by the Institutional Review Board at the Uni-
versity of Pittsburgh, Pittsburgh, PA, USA as exempt because it used
existing deidentiﬁed data.
2.2. Outcome
Medical claims of study participants were collected during the
follow-up period with primary or secondary ICD-9 codes for the
following events: acute myocardial infarction (ICD-9 code 410),
bradycardia (ICD-9 ¼ 427.89), syncope (ICD-9 ¼ 780.2), atrioven-
tricular block (ICD-9 ¼ 426.0), QT interval prolongation (ICD-
9 ¼ 426.82), and ventricular tachycardia (ICD-9 ¼ 427.1). The
outcome was an indicator variable for the occurrence of any of
these cardiovascular events.
2.3. Covariates
Covariates included demographic variables, predeﬁned clinical
characteristics, and empirical attributes from the medical and
pharmacy claims of each study participant. The demographic var-
iables and predeﬁned clinical characteristics were measured at
baseline, and the empirical attributes were measured both at
baseline and during follow-up period.
The demographic variables included age, race, and Medicaid
eligibility. The predeﬁned clinical factors included congestive heart
failure, hypertension, chronic kidney disease, diabetes, a history of
the following events: acute myocardial infarction, bradycardia,
syncope, QT prolongation, ventricular tachycardia, atrioventricular
block, stroke or transient ischemic attack (TIA), CMS priority types
of cancer, and number of other CMS priority comorbidities. To
identify a history of acute myocardial infarction, a history of stroke
or TIA, congestive heart failure, hypertension, chronic kidney dis-
ease, diabetes, a history of CMS priority types of cancer, and the
number of other CMS priority comorbidities (listed in Table 1), I
used CMS Chronic Condition Warehouse indicators that trace the
ﬁrst diagnosis of these conditions date back to January 1, 1999.17Indicator variables were deﬁned for each condition (the indicator
equaled 1 if the ﬁrst diagnosis happened prior to the index date,
0 otherwise). To identify a history of bradycardia, syncope, QT
prolongation, ventricular tachycardia, and atrioventricular block, I
collected themedical claims for study participants made during the
year prior to the index date and identiﬁedwhether they had at least
one claim with primary or secondary ICD-9 codes for any of these
events (ICD-9 codes are listed in section “Outcome”).
The empirical attributes included therapeutic class of any
medication used, an indicator of surgery, the ﬁrst three digits of the
ICD-9 diagnosis codes, and the ﬁrst three digits of the Healthcare
Common Procedure Coding System (HCPCS) codes. To identify the
therapeutic class of any medication used, the National Drug Code
for all medications from the pharmacy claims were extracted and
linkedwith the First Data Bank Enhanced Therapeutic Classiﬁcation
System, which includes 242 therapeutic classes of drugs. I extracted
all inpatient claims for each study participant and created an in-
dicator variable representing whether the patient had surgery. In
addition, I collected all medical claims and created indicator vari-
ables for each of the unique ﬁrst three digits of ICD-9 diagnosis
codes and unique ﬁrst three digits of the HCPCS codes. All empirical
attributes were identiﬁed in two time dimensions: ﬁrst, from the
claims made during the year prior to the initiation of an anti-
dementia drug; second, from the claims made during follow-up
period. I included empirical attributes measured during follow-up
period as covariates to enable the detection of possible in-
teractions between other therapeutic classes of drugs or clinical
I. Hernandez / Journal of Clinical Gerontology & Geriatrics 7 (2016) 77e82 79procedures and diagnosis and antidementia drugs. A total of 3056
empirical attributes were identiﬁed, which included 232 indicator
variables for unique therapeutic classes of drugs, 483 indicators for
unique ﬁrst three digits of ICD-9 diagnosis codes, 794 indicators for
unique ﬁrst three digits of HCPCS codes, and one indicator variable
for surgery, all deﬁned at baseline; and 242 indicators for unique
therapeutic class of drugs, 485 unique ﬁrst three digits of ICD-9
diagnosis codes, 818 unique ﬁrst three digits of the HCPCS codes,
and one indicator variable for surgery, all deﬁned during follow-up
period.2.4. Model learning
The data set was randomly split, and 50% of the observations
were used for training the algorithm and the remaining 50% for
validation. Because of the large number of potential covariates
(3077, 21 predeﬁned covariates and 3056 empirical attributes), I
constructed a four-step algorithm to identify the top predictors
(Figure 1).
(1) Selection of empirical attributes by prevalence prioritization.
This step excluded empirical attributes whose prevalence
was lower than 1%. The 1% threshold was ﬁxed according to
previous studies applying similar claims data mining tech-
niques in the prediction of clinical events.18 From the original
3056 empirical attributes, 2417 covariates were excluded.
(2) Univariate variable selection. This step ranked the 639
empirical attributes selected and the 21 predeﬁned cova-
riates according to the p value of univariate analysis. The
ranking was based on the p values of the Pearson Chi-squareTraining Set
Pre-defined 
Covariates
R
Empirical 
Attributes 
Step 1: Select Attributes with Prevalence >1%
Step 2: Univariate Variable Selection
Step 3: Multivariate Variable Selection
Final Model
Overall Study S
Figure 1. Overview of the algorithm. The ﬁgure shows the four steps in the construction an
set that contained 50% of the observations and a test set that contained the remaining 50%.
excluded (Step 1). Then, the selected empirical attributes and the predeﬁned covariates w
covariates and stepwise multivariate selection method, a logistic regressionwas built that pre
was validated on the test set (Step 4).statistic for categorical variables and on the p value of the F
statistic for continuous variables. Variables whose p value
was below the speciﬁed threshold were selected.
(3) Logistic regression with multivariate variable selection. To
further perform multivariate selection, a logistic regression
was built to predict the incidence of cardiovascular events
using forward stepwise variable selection. The initial model
only included the constant and at each step, likelihood ratio
tests were performed to determine whether the addition of
the most signiﬁcant covariate among those that had not
entered the model improved the predictive ability of the
model signiﬁcantly. At each step, the signiﬁcance of all var-
iables in the model was assessed and if any term could be
removed without signiﬁcantly decreasing the variance
explained by themodel, it was dropped. The p value for entry
of new attributes in themodel was ﬁxed at 0.05 and at 0.1 for
removal.
(4) Model validation. To evaluate the performance of the model,
I validated the ﬁnal logistic regression in the test set and
calculated the accuracy, the area under the curve (AUC),
speciﬁcity, sensitivity, positive predictive value, and negative
predictive value of the model.2.5. Parameter adjustment
The algorithm required one parameter: the p value for selection
of covariates by univariate selection. According to previous studies,
I searched the space of p values that allowed 0.5%,1%, 1.5%, and 2.5%
of the variables to be selected.18 I therefore constructed fourStep 4: Model Validation
andom Split
Test Set
ample 
d evaluation of the algorithm. First, the original data was randomly split into a training
Using the training set, empirical attributes whose prevalence was lower than 1% were
ere ranked according to the p value of univariate analysis (Step 2). Using the selected
dicted the incidence of any cardiovascular event (Step 3). This logistic regression model
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covariates selected by univariate selection, respectively. Four
models were compared using the following performance mea-
sures: accuracy, AUC, speciﬁcity, sensitivity, positive predictive
value, and negative predictive value.
3. Results
3.1. Patient characteristics and incidence of cardiovascular events
The sample included 160,096 patients, of which 31,698 (19.8%)
experienced a cardiovascular event during the follow-up period.
Syncope was the most common cardiovascular event; speciﬁcally,
18,710 (11.69%) of the study participants experienced a syncope.
The mean follow-up period was 2.77 years (interquartile range,
0.92e4.75 years).
Table 1 compares patient demographic and clinical character-
istics between those that experienced a cardiovascular event and
those who did not. Patients experiencing a cardiovascular event
were older, more likely to be male, and have a history of cardio-
vascular disease than those who did not experience an event.
3.2. Model evaluation
Four logistic regressionmodels were built, each of which used as
input the 0.5%, 1%, 1.5%, and 2.5% top predictors identiﬁed by uni-
variate selection. Using the top 0.5% variables as input, the logistic
regression built identiﬁed 10 risk factors for cardiovascular events.
When the percentage for univariate selection was ﬁxed at 1%, 1.5%,
and 2.5%, the models identiﬁed 13, 17, and 22 risk factors for car-
diovascular events, respectively. Table 2 compares the performance
measures of the four models. The model including the top 2.5%
predictors was the one with the highest accuracy, AUC, sensitivity,
positive predictive, power and negative predictive power. Specif-
ically, the accuracy of this model was 83.9%, the AUC 0.872, sensi-
tivity 45.7%, and speciﬁcity 93.3%.
3.3. Risk factors for experiencing cardiovascular events
Table 3 shows the risk factors for cardiovascular events identi-
ﬁed by each of the four models. Ischemic heart disease, number of
other CMS priority comorbidities, having a medical claim in the
year prior to treatment initiation with ICD-9 codes 427.XX (cardiac
dysrhythmias), 780.XX (general symptoms) or 786.XX (symptoms
involving the respiratory system or other chest symptoms), or
HCPCS codes 364XX (venipuncture), 930XX (electrocardiogram), or
992XX (hospital care or outpatient visit) were identiﬁed by four
models as risk factors for cardiovascular events.
Table 4 shows the odds ratio for cardiovascular events for each
of the variables identiﬁed as risk factors by themodel built with the
top 2.5% covariates. The odds of experiencing a cardiovascular
event while using antidementia drugs were 35% (95% CI, 28e42%)
higher among patients with ischemic heart disease than those
without it. In addition, having a history of stroke or TIA increasedTable 2
Comparison of model performance.a
Percentage of attributes allowed in univariate variable selection Accuracy (%)
0.5% Top attributes 82.2
1% Top attributes 83.0
1.5% Top attributes 83.4
2.5% Top attributes 83.9
AUC ¼ area under the curve; NPV ¼ negative predictive power; PPV ¼ positive predictiv
a The performance measures were obtained applying the logistic regression built to ththe odds of cardiovascular event by 15% (95% CI, 9e20%). Other risk
factors for cardiovascular events included having a diagnosis for
diabetes mellitus, essential hypertension, and occlusion and ste-
nosis of precerebral arteries, and undergoing radiologic examina-
tion or pacemaker evaluation, all in the year prior to antidementia
initiation.4. Discussion
Using large longitudinal claims data, I developed an algorithm
that identiﬁes the risk factors for cardiovascular events among AD
patients on antidementia drugs. With an accuracy of 84% and a
sensitivity of 93%, the algorithm identiﬁed 22 predictors for car-
diovascular events, including ischemic heart disease, congestive
heart failure, a history of syncope, a history of stroke or TIA, the
number of CMS priority comorbidities, and having a medical claim
with ICD-9 diagnosis code 427.XX (cardiac dysrhythmias), 250.XX
(diabetes mellitus), 786.XX (symptoms involving the respiratory
system or other chest symptoms) or HCPCS code 364XX (veni-
puncture), 710XX and 721XX (radiologic examinations), or 930XX
(electrocardiogram) in the year prior to antidementia initiation.
One may argue that patients with a history of cardiovascular
disease should have been excluded from the study sample because
it is not possible to determine whether the occurrence of cardio-
vascular events among these patients is a result of the use of
antidementia drugs or just a recurrence of their cardiovascular
condition. The study sample included patients with a history of
cardiovascular disease for two reasons: ﬁrst, as Table 1 shows, pa-
tients with a history of cardiovascular disease represent a sub-
stantial proportion of all the AD patients who used antidementia
drugs; and second, the recurrence rate of cardiovascular events was
higher among patients using antidementia drugs than in the gen-
eral population. For instance, the study sample included 7528
participants who had a history of myocardial infarction prior to the
initiation of an antidementia drug. The average follow-up time for
these 7528 participants was 2.5 years. In this period, 800 (10.63%)
experienced a recurrent myocardial infarction. This recurrence rate
is considerably higher than the risk of reinfarction for the general
population of patients surviving a heart attack, which has been
estimated at 6e7% in 3 years.19 Because this evidence suggests that
the use of antidementia drugs increases the risk of a cardiovascular
event regardless of the history of cardiovascular disease, patients
with prior cardiovascular disease were included in the study.
Nevertheless, this algorithm could be separately trained in future
studies in samples of patients with and without a history of car-
diovascular disease.
This study is subject to three main limitations. First, the sensi-
tivity (45.7%) and positive predictive power (62.5%) of the ﬁnal
model were low. However, this limitation does not invalidate the
results because the aim of the algorithm was not to predict which
patients will experience a cardiovascular event but to identify risk
factors for cardiovascular events. Second, overﬁtting is a main
limitation of most data mining models,20 and it is likely that the
model built with the top 2.5% covariates was subject toAUC Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
0.841 37.6 93.1 57.2 85.9
0.857 40.7 93.4 60.1 86.5
0.864 42.9 93.3 61.1 87.0
0.872 45.7 93.3 62.5 87.5
e power.
e test set.
Table 3
Risk factors for cardiovascular events identiﬁed by four models.
Variable Percentage of attributes allowed in univariate variable selection
2.5% Top attributes 1.5% Top attributes 1% Top attributes 0.5% Top attributes
Ischemic heart disease    
Congestive heart failure  
History of stroke or TIA 
Number of other CMS priority comorbidities    
History of Syncope   
Medical claim prior to treatment initiation with ICD-9 code
110.XX (Dermophytosis 
250.XX (Diabetes mellitus)  
401.XX (Essential hypertension)   
414.XX (Other forms of chronic ischemic heart disease) 
427.XX (Cardiac dysrhythmias)    
433.XX (Occlusion & stenosis of precerebral arteries) 
780.XX (General symptoms)    
786.XX (Symptoms involving respiratory system & other chest symptoms)    
Medical claim during follow-up period with HCPCS code
721XX (Other radiologic examination) 
870XX (Culture)  
Medical claim prior to treatment initiation with HCPCS code
117XX (Debridement of nail) 
364XX (Venipuncture)    
710XX (Radiologic examination of chest)   
721XX (Other radiologic examination) 
800XX (Metabolic panel)   
810XX (Urinalysis) 
930XX (Electrocardiogram)    
933XX (Echocardiography) 
937XX (Pacemaker evaluation)  
938XX (Noninvasive cerebrovascular studies) 
992XX (Hospital care or outpatient visit)    
CMS¼ Centers for Medicare and Medicaid Services; ICD-9 ¼ International Classiﬁcation of Diseases, Ninth Revision; HCPCS¼Healthcare Common Procedure Coding System;
TIA ¼ transient ischemic attack.
Table 4
Odds ratios for risk factors for cardiovascular events.a
Variable Odds ratio (95% CI)
Ischemic heart disease 1.35 (1.28e1.42)
Congestive heart failure 1.06 (1.01e1.12)
History of stroke or TIA 1.15 (1.09e1.20)
Number of other CMS priority comorbidities 1.15 (1.13e1.17)
History of Syncope 1.07 (1.00e1.13)
Medical claim prior to treatment initiation with ICD-9 code
110.XX (Dermophytosis) 1.19 (1.08e1.31)
250.XX (Diabetes mellitus) 1.17 (1.11e1.24)
401.XX (Essential hypertension) 1.11 (1.06e1.17)
427.XX (Cardiac dysrhythmias) 1.07 (1.00e1.13)
433.XX (Occlusion & stenosis of precerebral arteries) 1.18 (1.09e1.28)
780.XX (General symptoms) 1.17 (1.10e1.23)
786.XX (Symptoms involving respiratory system & other chest symptoms) 1.23 (1.17e1.30)
Medical claim during follow-up period with HCPCS code
721XX (Other radiologic examination) 1.11 (1.03e1.20)
870XX (Culture) 1.23 (1.10e1.36)
Medical claim prior to treatment initiation with HCPCS code
117XX (Debridement of nail) 1.19 (1.08e1.31)
364XX (Venipuncture) 1.13 (1.05e1.20)
721XX (Other radiologic examination) 1.17 (1.10e1.24)
800XX (Metabolic panel) 1.19 (1.12e1.28)
810XX (Urinalysis) 1.07 (1.01e1.13)
930XX (Electrocardiogram) 1.09 (1.03e1.15)
937XX (Pacemaker evaluation) 2.33 (2.07e2.62)
992XX (Hospital care or outpatient visit) 2.35 (2.21e2.50)
CI ¼ conﬁdence interval; CMS¼ Centers for Medicare and Medicaid Services; HCPCS¼Healthcare Common Procedure Coding
System; ICD-9 ¼ International Classiﬁcation of Diseases, Ninth Revision; OR ¼ odds ratio; TIA ¼ transient ischemic attack.
a Results from the model built when the percentage of variables allowed for univariate selection was ﬁxed at 2.5%.
I. Hernandez / Journal of Clinical Gerontology & Geriatrics 7 (2016) 77e82 81overparametrization. This would explain why some factors were
identiﬁed as risk factors for cardiovascular events, even though
there is no clinical rationale behind such association. Third, thestudy sample included both patients taking AChEIs andmemantine.
Because of their different mechanisms of action, risk factors for
cardiovascular events may differ between patients taking AChEIs
I. Hernandez / Journal of Clinical Gerontology & Geriatrics 7 (2016) 77e8282and memantine. In future research, the algorithm could be sepa-
rately applied in samples of patients using AChEIs and memantine.
Nevertheless, this study is an important ﬁrst step in the use of
large longitudinal claims data in the identiﬁcation of risk factors for
side effects of pharmacological treatments. Similar approaches
could be easily used in the identiﬁcation of risk factors for adverse
events of other medications for two reasons. First, this algorithm is
less computationally intensive than standard stepwise pro-
cedures21; nevertheless, the accuracy and discriminatory power of
the model are excellent. Second, the results of this algorithm are
easily interpretable. One of the main limitations of alternative
machine learning techniques is their complexity, often producing
complicated models whose results are difﬁcult to interpret by cli-
nicians. However, the ﬁnal product of this algorithm was a logistic
regression, which provides easily interpretable odds ratios for the
risk of cardiovascular events for each covariate.
In conclusion, I built an algorithm that exploits high-
dimensional claims data to identify risk factors for cardiovascular
events among AD patients on antidementia drugs with an accuracy
of 84% and sensitivity of 93%. I identiﬁed 22 predictors for cardio-
vascular events, including a history of several cardiovascular con-
ditions and undergoing cardiovascular procedures. These results
could guide prescribers in the identiﬁcation of patients at high risk
of experiencing cardiovascular events with antidementia drugs and
who should be prescribed these drugs with caution.
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